Foley & Lardner LLP senior counsel Roberto Fernandez assessed new procedures at the U.S. Patent and Trademark Office (USPTO) in the Law360 article, “New Procedures Expected To Result In More PTAB Denials.”
Commenting on a memo from the acting USPTO director intended to address the Patent Trial and Appeal Board’s (PTAB) “workload needs,” Fernandez said “it’s almost as it that’s now a factor in the discretionary denial analysis, which previously didn’t exist.”
“I think what you’ll see is each of these bullet points fleshed out in short order,” and that will “lay the groundwork for future PTAB institution decisions,” he added.
(Subscription required)
People
Related News
June 23, 2026
In the News
John P. Riley Spotlighted as a Most Promising Newcomer Finalist in Law.com's California Legal Awards
Foley & Lardner LLP associate John P. Riley is recognized in Law.com as a Most Promising Newcomer finalist for the 2026 California Legal Awards.
June 23, 2026
In the News
William Holtz on Regulatory Balance in Peptide Market
Foley & Lardner LLP of counsel William Holtz was quoted in The Wall Street Journal’s article, “Businesses Are Taking Risks to Cash In on the Peptide Gold Rush,” examining the risks and regulatory challenges facing compounding pharmacies supplying peptides.
June 22, 2026
In the News
Aaron Maguregui Authors Article on Building Scalable, Secure AI Strategies
Foley & Lardner LLP partner Aaron Maguregui authored the HealthTech article, “A Digital Health CEO’s Guide to Fast, Secure Scaling of AI,” offering guidance to digital health leaders on artificial intelligence scaling.